Shire plc made an equity investment in Rani Therapeutics as part of an agreement to develop the latter's pill delivery technology.
Shire intends to research Rani's pill technology for the oral delivery of factor VIII therapy for patients with hemophilia A, including the right to license it following completion of feasibility studies.
Hemophilia A is blood disorder caused by a deficiency of functional plasma clotting factor VIII, which may be inherited or arise from spontaneous mutation.
The specific terms of the deal were not disclosed.
